Serum angiotensin-converting enzyme (SACE) levels are in uenced by genetic polymorphism. Interpretation of serum levels with the appropriate genotypic reference range improves the diagnostic sensitivity of the assay for sarcoidosis. SACE assays are performed by a large number of routine clinical laboratories. However, there is no external quality assessment (EQA) for SACE other than an informal regional scheme. This showed analytical performance of SACE assays to be poor, with a diversity of reference ranges, leading to widely disparate clinical classi cation of EQA samples. Genetic polymorphism combined with poor analytical performance suggest that perhaps SACE assays should revert to being the province of specialized laboratories.
Introduction
In a review article published in the Annals of Clinical Biochemistry in 1989, Studdy and Bird concluded that Serum angiotensin-converting enzyme (SACE, EC 3.4.15.1) is best performed at a regional or supraregional centre, rather than at a non-specialized district laboratory'. 1 In a survey of over 50 clinical biochemistry laboratories in the Thames health regions conducted in 1994 it emerged that nearly half were performing their own SACE assays. 2 Until recently, there was no external quality assessment (EQA) available for SACE, although a regional scheme provided some between-laboratory comparisons. 3 The performance of laboratories in the regional scheme gives some cause for concern, and this personal view will o¡er an analysis of these problems.
Although the ¢rst serum assay for angiotensinconverting enzyme was described in 1970, 4 interest in SACE began in 1975 with Lieberman's observation that levels were raised in sarcoidosis. 5 However, the usefulness of SACE as a diagnostic test for sarcoid was limited by a lack of sensitivity and speci¢city with positive and negative predictive values of 84% and 74%, respectively, in one series. 1 Many other conditions have also been shown to be associated occasionally with altered SACE levels 5^13 (Table 1) . Thus, monitoring of response to treatment in sarcoidosis would seem to be the most useful role of the assay. 1 There have been some reports of age and gender di¡erences in SACE, children between 4 and 18 years having higher values than adults, and men having slightly higher values than women. 14, 15 However, most authors have not noted any sex di¡erences. 6 SACE levels remain within narrow limits in an individual but vary widely among individuals. 16 It is now known that this variation is due to a genetic polymorphism that in£uences SACE levels. 17
Genetic polymorphism of angiotensinconverting enzyme gene
It has been demonstrated that insertion/deletion (I/D) polymorphisms occur, characterized by the presence (I) or absence (D) of a 287 base-pair fragment in intron 16 of the angiotensin-converting enzyme (ACE) gene on chromosome 17. 17 Each of the alleles can be either I or D giving rise to the three genotypes II, DD and ID. These are present in white populations approximately in the proportions of 0¢20, 0¢30 and 0¢50, respectively, although there is considerable variation among white populations in di¡erent countries, and even among control groups within one country in some small studies. 18 Higher incidence of the D allele has been reported in black populations, but it is lower than whites in Chinese and Japanese. 19 
Genetic polymorphism and disease
There have been numerous and con£icting reports about an association between the DD genotype and disease, especially a number of manifestations of cardiovascular disease (e.g. hypertension, myocardial infarction, cardiac hypertrophy). In early studies, the numbers were small and technical di¤culties with the polymerase chain reaction leading to overdetection of the D allele were implicated as a potential cause for con£icting results. 20, 21 Recent meta-analyses combining over100 reports covering many thousands of subjects have supported the associations with DD genotype and ischaemic stroke, diabetic nephropathy, coronary heart disease and myocardial infarction but failed to show associations with diabetic retinopathy, hypertension, left ventricular hypertrophy and hypertrophic cardiomyopathy. 23, 24 In£ation of the DD associations by positive result publication bias was also suggested. 23 The topic remains controversial, 18 particularly with respect to hypertension in which numerous sets of opposing ¢ndings have been reported. 25 Indeed, the picture has been further clouded by a recent report in which the D allele was found with increased frequency in centenarianst he opposite of what might be expected from the risk associations previously described. 26 Recently, a second polymorphism (PstI) at intron 7 in the ACE gene has been reported to be associated with risk of developing nephropathy in type 1 but not type 2 diabetes. 27, 28 
Genetic polymorphism and serum angiotensinconverting enzyme activity
Since I/D polymorphism was discovered it has been demonstrated repeatedly that ACE activity in plasma is Veno-occlusive disease 6 Hyperthyroidism 6 ACE inhibitors 6 Alcoholic liver disease 6 Smoking 12 Primary biliary cirrhosis 6 Hormone replacement therapy 13 Human immunode ciency virus infection 7 Chronic fatigue syndrome 8 Diabetes mellitus 9 Cardiovascular disease risk 10 Multiple sclerosis 11 in£uenced by the ACE genotype. DD individuals have nearly twice the SACE activity of II individuals, with values from ID individuals being intermediate. 26,29^34 Tissue ACE activities (lymphocytes and heart) were also higher in DD individuals. 35, 36 This discovery has important implications for the interpretation of SACE levels in disease. Small increases in ACE activity in the genetically low (II) group will be masked when compared with a mixed reference population of the three genotypes. This may be one reason for the relatively low sensitivity of SACE in the detection of sarcoidosis. Indeed, the in£uence of polymorphism on the sensitivity of SACE for sarcoidosis has been investigated, and as might have been predicted, the use of genotype-speci¢c reference ranges makes SACE somewhat more sensitive. 30, 33, 37, 38 However, it would be unrealistic to expect this approach to be within easy reach of routine clinical chemistry departments, as ACE I/D genotyping would be required on every patient being investigated for sarcoidosis. The recently discovered PstI polymorphism does not seem to in£uence serum ACE levels. 27
Analysis of serum angiotensin-converting enzyme activity
Early assays for ACE made use of its physiological substrate angiotensin I, and products may be detected by bioassay, immunoassay, high-performance liquid chromatography (HPLC) or chemical methods. 6 The production of synthetic substrates such as hippurylglycylglycine and hippurylhistidylleucine in the late 1960s was followed by the development of more manageable assays which were then applied to serum, and some of these are still in use today. However, it was the introduction of furylacryloylphenylalanylglycylglycine (FAPGG) by Holmquist et al. in 1979 39 that led to a series of automated direct spectrophotometric assays for SACE. 40^49 Commercial kits based on this substrate were introduced into the UK by Sigma (Poole, Dorset, UK) in 1986 and by Buhlmann in 1992. As these methods appear to be the most popular in the UK, they will be considered in greater detail.
Analytical methods using FAPGG as substrate
Principle ACE catalyses the conversion of FAPGG to furylacryloylphenylalanine (FAP) and glycylglycine. There is a slight blue shift in the absorbance spectrum of FAP compared to that of FAPGG and the di¡erence spectrum shows a well-de¢ned peak at 328 nm. There is a fall in absorbance as the reaction proceeds. A comparison of some features of the many published direct spectrophotometric assays is shown in Table 2 .
Factors affecting assay performance Wavelength
The peak at 328 nm is unsuitable because of interference from the high absorbance of the substrate at that wavelength. Three compromise wavelengths have been used. The largest change in absorbance is at 334 nm, but the initial absorbance is highest at this wavelength. A 340 nm wavelength is popular because it is readily available on automated analysers but 345 nm is preferred by some authors who claim greater linearity at this wavelength with no loss in sensitivity. The accuracy of the wavelength setting is critical, as all three wavelengths lie on a steep part of the absorbance di¡erence spectrum curve.
Calibration
Calibration of the assays depends critically on the absorbance di¡erence coe¤cient between FAPGG and FAP (¢A). Three approaches to the measurement of ¢A have been described: to allow the enzyme reaction to continue to completion; to prepare mixtures of substrate and product from pure chemicals; and, to measure the absorbance of pure substrate and pure product separately and deduce the ¢A. 49 In theory, if routine analyses are carried out using the same equipment as is used for determining ¢A, di¡erences should be self-correcting, allowing comparability between di¡erent laboratories.
Substrate molarity
The K m for ACE has been reported to be about 0 ¢ 31mmol/ L. 40 Because both FAPGG and FAP absorb strongly, even at wavelengths removed from the di¡erence spectrum maximum, all the direct spectrophotometric assays have to be performed at substrate concentrations which are unsatisfactorily low ( Table  2 ). Buttery and Stuart 49 reported higher ACE activities when substrate concentrations were increased within the range of sub-optimal concentrations shown in Table 2 . Also, an HPLC assay has been described 50 in which a higher substrate concentration (10¢0 mmol/ L) could be used because of the separation of substrate from product before taking readings. In other respects this assay is comparable to the direct assays, but it showed a much higher range of activities (74^261 U/L) in normals. Thus, it seems likely that substrate concentration in£uences the results obtained.
Buffers
Three bu¡ers have been used, all at pH 8¢2. There are contradictions in the literature as to which gives the highest activity and thus their in£uence on the assay is uncertain, although probably not large. All the direct methods incorporate chloride ions, an essential activator, at between 200 and 300 mmol/ L.
Sample volume
The ratio of sample to reagent varies between 1: 2¢3 and 1: 19 in the published methods. There is a suggestion that ratios less than 1: 9 may lead to low results due to the presence of endogenous inhibitors.
Lag phase
Although most methods incorporate a delay before initiation of readings, the nature of the lag phase has never been fully investigated. Roulston and Allan 47 and Buttery and Stuart 49 both suggest it varies from sample to sample and may be as much as 8 min. Clearly, any variation may in£uence results. Table 2 shows the diversity of reference ranges using FAPGG methods that had been published before the e¡ect of genetic polymorphism was known. Possible reasons for these di¡erences have been discussed and have concentrated mainly on the variations in assay protocol described above. 51^53 Genetic polymorphism clearly compounds the di¤culties of establishing reference ranges. This, combined with the small numbers in the reference populations, may have led to poorly de¢ned and inappropriate ranges. Unfortunately, ACE genotyping is not yet available to the average laboratory.
Reference ranges

External quality assessment
In 1994 the North West Thames Quality Assurance Working Party introduced an external quality assessment (EQA) scheme for SACE. Twenty-four out of 54 laboratories canvassed in the Thames health regions reported that they assayed SACE, showing that its measurement was widespread and not con¢ned to specialist laboratories. These laboratories then participated in an analytical survey, in which two samples of lyophiliz ed human serum from a commercial source were distributed. The results of the survey were published in 1995 2 and are summarized in Table 3 and Figs 1 and 2 . Twenty-three out of the 24 laboratories used FAPGG as substrate, 15 used the Sigma kit, and nine used in-house assays adapted from the literature. Seven of the 15 Sigma kit users quoted reference ranges di¡erent from the kit insert range of 8^52 U/L, with lower reference limits varying from eight to 20 and upper limits from 53 to 90 U/L. These ranges were derived from`normals'or`patients and normals', or had been extrapolated by comparison with a previous provider laboratory. No laboratory declared a genotype-speci¢c reference range. Very similar results were obtained in three subsequent sample distributions 3 and there has been only a modest improvement up to and including the thirteenth distribution (October 2000), summarized in Table 4 , in which numbers have increased due to participation of laboratories from other parts of the UK.
The EQA scheme has shown that between-laboratory coe¤cients of variation (CV) for the measurement of SACE using a single manufacturer's reagents range from 10% to 20%. This compares badly with CV for enzymes in the UK NEQAS general clinical chemistry group which are usually well below 10% for method groups using reagents from a single source. On the other hand, it was perhaps to be expected that laboratories using di¡erent in-house methods would show much higher between-laboratory CV.
In an attempt to validate between-laboratory comparisons, the results were expressed as per cent of the laboratories'own upper limits of normal. However, while in-house assay CV improved slightly with this manoeuvre, those for the Sigma kit group showed little change or were made worse. 
Reasons for poor assay performance in external quality assessment schemes
The use of FAPGG substrate requires that small absorbance changes are measured at wavelengths close to the absorbance peak of FAPGG/FAP. This may contribute towards analytical imprecision. However, modern automatic analysers can usually accommodate such small absorbance changes. Indeed, among the authors of the methods listed in Table 2 , all except two reported within-and between-assay CV below 5% (the exceptions were above 5% for low mean values, but still below 10%). 44, 47 The one published evaluation of the Sigma kit method reported CV of 0¢9% and 2¢3% within-assay and 1¢5% and 3¢1% between-assay. 54 The high between-laboratory imprecision of the Sigma kit users in the NW Thames EQA scheme is di¤cult to explain, because the only di¡erences between these assays appears to have been in the time course of the reaction due to the constraints of di¡erent automated systems. This is a potential problem if a long lag phase is present in an individual sample. 49 It should be noted that the substrate concentration in the Sigma kit reagent is lower than any of the other methods outlined in Table 2 , but it is di¤cult to say whether this contributes to the poor performance. A calibrator is provided by Sigma, thus eliminating one potential source of variation.
Among in-house assay users, there were di¡erences in wavelength, bu¡er, sample volume, time course, substrate molarity and calibration procedure. It was hardly surprising that between-laboratory CV was high.
Expressing results as per cent upper limit of the reference range was intended to take account of method di¡erences as well as examining the clinical performance of the participating laboratories. The CV in the`in-house' group showed some reduction, although the spread was still very large when expressed in this way; however, there was little change in the Sigma groups, presumably due to the widely di¡ering reference ranges used by participants. Indeed, an EQA serum sample with a consensus activity near the upper reference limit (sample 1a, Fig. 2) gave an overall spread of results from 22% to 149% of individual laboratories upper reference limits (60^135% for Sigma kit users), i.e. from low-normal to clearly raised. The upper reference limits of the locally derived ranges of laboratories using the Sigma kit varied between 53 and 90 U/L (Sigma range: 8^52 U/L).
The poor analytical performance revealed by the EQA scheme is compounded by the diversity of reference ranges used by participant laboratories, and together these have led to an unacceptable performance in the measurement of SACE.
Conclusion
With few exceptions, reference ranges for serum angiotensin-converting enzyme activity have been derived without taking ACE genetic polymorphism into account. 30, 33, 37, 38 This undoubtedly contributes to the low sensitivity of SACE for the detection of sarcoidosis. Also, performance of SACE assays by a sample of UK laboratories, in conjunction with widely di¡ering reference ranges for the same assay method, has led to unacceptable between-laboratory variation in the interpretation of SACE results.
While this situation remains, it is important to remember that SACE is most useful in monitoring response to treatment in diagnosed sarcoidosis. 1 As ACE genotyping becomes more accessible, reliable genotype-based reference ranges may become available and a diagnostic role for SACE may emerge. In the meantime, perhaps the measurement of serum ACE should once more become the province of the specialist laboratory, i.e. one able to o¡er genotyping to aid in the interpretation of results.
